Bente Bull-Hansen and Anette Weyergang from Kristian Berg's "Group of Photochemical Internalization (PCI)" at the Department of Radiation Biology is the first- and senior/corresponding- author of a paper entitled "Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; impact of HER2 expression on treatment outcome" accepted for publication in the high ranked drug delivery journal "Journal of Controlled Release" (2013 impact factor 7.63).
The main aim of the study was to use PCI for the intracellular delivery of the HER2 targeted fusion toxin MH3-B1/rGel to HER2 expression breast cancer. However, it was found that both HER2 high- and low expressing breast cancer was responsive to the treatment, and that the cellular sensitivity to PCI and the toxin itself masked the correlation between HER2 expression and treatment outcome. The authors concludes that PCI of MH3-B1/rGel may be a possible treatment approach not only for HER2-overexpressing tumors but also for tumors with heterogeneous levels of HER2 as well as for triple negative breast cancer.
Download graphical abstract (Powerpoint pptx format)
Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; impact of HER2 expression on treatment outcome.
Bull-Hansen B, Cao Y, Berg K, Skarpen E, Rosenblum MG, Weyergang A.
J Control Release. 2014 Mar 14. pii: S0168-3659(14)00148-5. doi: 10.1016/j.jconrel.2014.03.014. [Epub ahead of print]
Kristian Berg'g group - Photochemical internalisation (PCI)
Department of Radiation Biology